Lal Ratnesh, Lin Hai, Quist Arjan P
Center for Nanomedicine, University of Chicago, 5841 S. Maryland Ave., MC 6076, Chicago, IL 60637, USA.
Biochim Biophys Acta. 2007 Aug;1768(8):1966-75. doi: 10.1016/j.bbamem.2007.04.021. Epub 2007 May 3.
Alzheimer's disease (AD) is a protein misfolding disease. Early hypothesis of AD pathology posits that 39-43 AA long misfolded amyloid beta (Abeta) peptide forms a fibrillar structure and induces pathophysiological response by destabilizing cellular ionic homeostasis. Loss of cell ionic homeostasis is believed to be either indirectly due to amyloid beta-induced oxidative stress or directly by its interaction with the cell membrane and/or activating pathways for ion exchange. Significantly though, no Abeta specific cell membrane receptors are known and oxidative stress mediated pathology is only partial and indirect. Most importantly, recent studies strongly indicate that amyloid fibrils may not by themselves cause AD pathology. Subsequently, a competing hypothesis has been proposed wherein amyloid derived diffusible ligands (ADDLs) that are large Abeta oligomers (approximately >60 kDa), mediate AD pathology. No structural details, however, of these large globular units exist nor is there any known suitable mechanism by which they would induce AD pathology. Experimental data indicate that they alter cell viability by non-specifically changing the plasma membrane stability and increasing the overall ionic leakiness. The relevance of this non-specific mechanism for AD-specific pathology seems limited. Here, we provide a viable new paradigm: AD pathology mediated by amyloid ion channels made of small Abeta oligomers (trimers to octamers). This review is focused to 3D structural analysis of the Abeta channel. The presence of amyloid channels is consistent with electrophysiological and cell biology studies summarized in companion reviews in this special issue. They show ion channel-like activity and channel-mediated cell toxicity. Amyloid ion channels with defined gating and pharmacological agents would provide a tangible target for designing therapeutics for AD pathology.
阿尔茨海默病(AD)是一种蛋白质错误折叠疾病。AD病理学的早期假说是,39 - 43个氨基酸长的错误折叠淀粉样β(Aβ)肽形成纤维状结构,并通过破坏细胞离子稳态诱导病理生理反应。细胞离子稳态的丧失被认为要么是间接由于淀粉样β诱导的氧化应激,要么是直接由于其与细胞膜的相互作用和/或激活离子交换途径。然而,值得注意的是,目前尚不清楚有任何Aβ特异性细胞膜受体,并且氧化应激介导的病理学只是部分的和间接的。最重要的是,最近的研究强烈表明淀粉样纤维本身可能不会导致AD病理学。随后,有人提出了一种竞争性假说,即淀粉样衍生的可扩散配体(ADDLs),即大的Aβ寡聚体(约>60 kDa),介导AD病理学。然而,这些大的球状单元没有结构细节,也没有任何已知的合适机制来解释它们如何诱导AD病理学。实验数据表明,它们通过非特异性地改变质膜稳定性和增加整体离子泄漏来改变细胞活力。这种非特异性机制与AD特异性病理学的相关性似乎有限。在这里,我们提供了一个可行的新范式:由小Aβ寡聚体(三聚体至八聚体)构成的淀粉样离子通道介导AD病理学。本综述着重于Aβ通道的三维结构分析。淀粉样通道的存在与本期特刊中配套综述所总结的电生理学和细胞生物学研究一致。它们表现出离子通道样活性和通道介导的细胞毒性。具有明确门控和药理作用的淀粉样离子通道将为设计针对AD病理学的治疗方法提供一个切实可行的靶点。